conclusions patients who live with implantable cardioverter defibrillators face many concerns and challenges. therefore, the role of nurses in teaching patients before and after implementation is very important. results the challenges of living with an implantable cardioverter defibrillator include: living with fear, concerns about the future, concerns about device malfunction, fearing death du...

BACKGROUND There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients. Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions. AIM To determine patient awareness, preferences and timing of implantable cardioverter-defib...

BACKGROUND Cardiac arrest due to ventricular arrhythmia in the absence of a reversible cause or contraindication has been a class I indication for insertion of an implantable cardioverter defibrillator since 1998. We compared and contrasted the use of implantable cardioverter defibrillator therapy in Canada and the United States among adults who survived a cardiac arrest. METHOD Data on hospi...

INTRODUCTION AND OBJECTIVES The authors summarize the findings of the Spanish Implantable Cardioverter-Defibrillator Registry for 2010 compiled by the Spanish Society of Cardiology Working Group on Implantable Cardioverter-Defibrillators. METHODS Members of the Spanish Society of Cardiology were prospectively surveyed; data were recorded voluntarily by each implantation team on one-page quest...

OBJECTIVE Implantable cardioverter-defibrillator has become the first-line therapy for prevention of sudden cardiac death. Controversial results still exist regarding the effectiveness of implantable cardioverter-defibrillator (ICD) in non-ischemic heart failure. METHODS The PubMed, Embase, and Cochrane Central databases were searched for randomized trials comparing implantable cardioverter-d...

patient with cardiac arrest, as initial presentation of the underlying cardiac disease, who receives an implantable cardioverter-defibrillator, cost cannot be evaluated, unless the first line therapeutic option for these patients is not an implantable cardioverter-defibrillator. Another approach could be to randomize these patients to an implantable cardioverter-defibrillator or to other forms ...

Fro of D Re Hu an Me rec Me rel Ma OBJECTIVES This study aims to conduct a meta-analysis comparing efficacy and safety outcomes between subcutaneous implantable cardioverter-defibrillator (S-ICD) and transvenous implantable cardioverter-defibrillator

AIMS Benefits and complications of postoperative implantable cardioverter-defibrillator tests are controversial matters. This study sought to assess the necessity of defibrillation function tests after implantation. METHODS AND RESULTS We retrospectively analysed 1007 implantable cardioverter-defibrillator tests in 587 systems and 556 patients. Nine hundred and thirty implantable cardioverter...